Drug Trial Radar · NCT00892281
ORCA - Oracea® for Rosacea: A Community-based Assessment
Last checked: Nov 19, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,421
Actual
Start
Apr 2009
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
Conditions
- Rosacea
Interventions
doxycycline (Oracea®) 40 mg modified release as monotherapyDrug
Take once daily in the morning
doxycycline (Oracea®) 40 mg modified release as add-on therapyDrug
Take once daily in the morning
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Investigator's Global Assessment (IGA) Score From Baseline to EndpointTime frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
REGISTRAT® - MAP1, Inc. (CRO)
Lexington, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.